Pinebridge Investments L.P. raised its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 48.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,675 shares of the health services provider’s stock after purchasing an additional 15,162 shares during the quarter. Pinebridge Investments L.P.’s holdings in Amedisys were worth $2,460,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UBS Asset Management Americas Inc. lifted its holdings in Amedisys by 23.9% during the second quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock valued at $915,000 after purchasing an additional 2,812 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Amedisys by 29.7% during the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after purchasing an additional 339,825 shares during the last quarter. Copper Rock Capital Partners LLC lifted its holdings in Amedisys by 3.6% during the fourth quarter. Copper Rock Capital Partners LLC now owns 596,014 shares of the health services provider’s stock valued at $31,386,000 after purchasing an additional 20,699 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in Amedisys by 15.8% during the third quarter. Sterling Capital Management LLC now owns 16,654 shares of the health services provider’s stock valued at $932,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Amedisys during the third quarter valued at about $1,212,000. 91.81% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have commented on AMED shares. Royal Bank of Canada reaffirmed a “hold” rating on shares of Amedisys in a report on Monday, October 23rd. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and upped their price objective for the company from $55.00 to $65.00 in a report on Thursday, November 2nd. Benchmark raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a report on Thursday, November 2nd. Craig Hallum reaffirmed a “buy” rating and set a $68.00 price objective (up from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Finally, Robert W. Baird upped their price target on Amedisys from $50.00 to $60.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $60.64.
Shares of Amedisys Inc (AMED) opened at $56.46 on Tuesday. Amedisys Inc has a 52-week low of $45.60 and a 52-week high of $65.91. The firm has a market capitalization of $1,916.07, a PE ratio of 27.01, a PEG ratio of 1.15 and a beta of 0.73. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.16.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.